SCHAUMBURG, Ill. and SOPHIA ANTIPOLIS, France, Sept. 11, 2013 /PRNewswire/ -- Jeannette R. Jakus, MD, MBA, has been selected as the 2013 recipient of the American Academy of Dermatology Translational Biotechnology Fellowship, a partnership of the American Academy of Dermatology and Galderma Research & Development, SNC.
As part of the fellowship, Dr. Jakus will work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis, France, beginning in fall 2013. Sophia Antipolis is the largest corporate-funded facility in the world dedicated to dermatology.
A graduate of Jefferson Medical College, Philadelphia, Dr. Jakus has completed a residency in dermatology and a fellowship in pediatric dermatology at SUNY Downstate Medical Center, Brooklyn, N.Y., and a residency in pediatrics at Mount Sinai Medical Center, New York, N.Y. She also has a master's of business administration from Columbia Business School, New York, N.Y.
The application for the fall 2014 Translational Biotechnology Fellowship is available at www.aad.org/biotechfellowship. Applications are due by October 15, 2013. The 2014 recipient will be notified in December 2013. Preference will be given to candidates who are in their last year of residency in an accredited American College of Graduate Medical Education dermatology residency program. Candidates must be a physician member of the Academy who will have satisfactorily completed a residency no more than three years before the planned start date. The selected candidate will receive a stipend to cover his or her costs during the term of the fellowship.
About the American Academy of Dermatology
Celebrating 75 years of promoting skin, hair and nail health
Headquartered in Schaumburg, Ill., the American Academy of Dermatology (Academy), founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 17,000 physicians worldwide, the Academy is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. For more information, contact the Academy at 1-888-462-DERM (3376) or www.aad.org. Follow the Academy on Facebook (American Academy of Dermatology) or Twitter (@AADskin).
A world leading medical company exclusively focused on dermatology
Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 33 wholly-owned affiliates with a worldwide network of distributors and more than 5,000 employees. Galderma's extensive product portfolio is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.
With approximately 20% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world's leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.
Strategic brands include Epiduo®, Oracea®, Mirvaso®, Clobex®, Differin®, Rozex®/MetroGel®, Silkis®/Vectical®, Tri-Luma®, Loceryl®, Cetaphil®, Metvix®, Azzalure®, Restylane® and Emervel®.
For more information, please visit www.galderma.com
About Sophia Antipolis: the world's largest R&D center specialized in dermatology
Galderma's five R&D centers are located in France, Sweden, Switzerland, the United States and Japan and are playing a key role in the discovering and developing of innovative medical solutions for the global dermatology market. Located in southeast France, Galderma's Sophia Antipolis facility is the largest laboratory in the world dedicated exclusively to dermatology. This state-of-the-art center is the birthplace of the adapalene molecule, an active ingredient in Differin® Gel and Epiduo® Gel. Five hundred scientists and support staff work at the center which hosts all of Galderma's in-house research, preclinical and core development (clinical, pharmaceutical and biometric) activities. Since its opening at the end of 2006, this 270,000 sq. feet facility accommodates our scientists with expertise ranging from genomics to proteomics, from high throughput technologies such as screening, chemistry and toxicogenomics to clinical activities in early and full development.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
|SOURCE Galderma Laboratories|
Copyright©2012 PR Newswire.
All rights reserved